Home / Stocks / Syncom Formu (i) Ltd
SYNCOMF

Syncom Formu (i) Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹22.09

Change

+0.01 (0.05%)

Open

₹22.08

Prev. Close

₹22.08

Day High

₹22.35

Day Low

₹21.51

Volume Analysis

Traded

15,186,461

Delivered

3,555,701

Delivery %

23.41%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (20.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (56.8%)
  • •Strong 3-year revenue growth (30.0%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹23.29 ₹22.82 ₹22.45 ₹21.98 ₹21.61 ₹21.14 ₹20.77
Fibonacci ₹22.82 ₹22.5 ₹22.3 ₹21.98 ₹21.66 ₹21.46 ₹21.14
Camarilla ₹22.32 ₹22.24 ₹22.17 ₹21.98 ₹22.01 ₹21.94 ₹21.86

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+56.89%

1 Week

+9.14%

1 Month

+0.09%

3 Months

+36.86%

6 Months

+54.04%

1 Year

+38.06%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹9.55

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

19.22%

Net margin 18.53% × asset turnover 0.85x × equity multiplier 1.22x

Company Overview

Sector

Healthcare

Market Cap

₹1,907 Cr

P/E (TTM)

20.0

ROE

17.6%

Book Value

₹5.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Syncom Formu (i) Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 73/100. The strongest factor is Financial Strength (100/100), while Risk & Volatility (48/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%). Strong 3-year EPS growth (56.8%).

TopFund Score — Fundamentals Quality

73/100 — Good

Data confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

100

Valuation

51

Cash Flow

53

Corporate Governance

76

Momentum

58

Institutional Ownership

53

Business Quality

88

Risk & Volatility

48

Liquidity

53

From Screener.in

  • +Company is almost debt free.
  • +Debtor days have improved from 104 to 82.6 days.
  • −Earnings include an other income of Rs.34.0 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Submission of Press Clipping regarding publication of extract of Unaudited Standalone and Consolidated Financial Results for the Quarter/Half Year ended on 30th September, 2026

Certificate for Compliance of Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th September, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 64 65 75 87 102 128 149 117 122 115 135 126 142
Expenses + 57 58 65 77 90 113 131 101 103 94 113 99 110
Operating Profit 6 7 9 10 12 15 18 16 18 21 22 26 32
OPM % 10.0% 11.0% 13.0% 12.0% 12.0% 12.0% 12.0% 14.0% 15.0% 18.0% 16.0% 21.0% 22.0%
Other Income + 4 5 3 1 4 4 7 6 5 6 15 8 6
Interest 1 1 1 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 2 2 2
Profit before tax 8 9 10 10 15 17 23 20 22 25 34 32 36
Tax % 23.0% 25.0% 26.0% 24.0% 25.0% 25.0% 24.0% 22.0% 25.0% 25.0% 25.0% 23.0% 26.0%
Net Profit + 7 7 7 8 11 13 18 16 17 19 25 25 27
EPS in Rs 0 0 0 0 0 0 0 0 0 0 0 0 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 17 14 22 46 60 96 100 34 19 -10 -9 7 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 115 151 173 184 185 216 222 262 463 488 518
Expenses + 104 135 155 167 168 196 202 232 408 411 417
Operating Profit 11 16 18 17 17 20 20 30 54 77 101
OPM % 9.0% 11.0% 11.0% 9.0% 9.0% 9.0% 9.0% 11.0% 12.0% 16.0% 20.0%
Other Income + 1 1 1 3 3 12 15 14 17 31 34
Interest 1 0 0 0 0 2 3 5 1 1 1
Depreciation 3 3 3 3 3 4 5 5 5 7 7
Profit before tax 8 14 16 16 16 26 27 34 66 101 127
Tax % 33.0% 33.0% 38.0% 36.0% 34.0% 24.0% 24.0% 25.0% 25.0% 24.0% —
Net Profit + 6 9 10 10 11 20 20 25 49 76 96
EPS in Rs 0 0 0 0 0 0 0 0 1 1 1
Dividend Payout % 24.0% 17.0% 16.0% 15.0% 15.0% 13.0% 0.0% 0.0% 0.0% 12.0% —
Sales growth — 32 15 6 0 — 3 18 77 5 1

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 65 17 22 31 39 136 162 194 248 321 376
Borrowings + 2 3 6 6 12 58 83 72 5 1 16
Other Liabilities + 33 42 31 61 50 28 39 44 67 117 87
Total Liabilities 123 140 138 175 180 308 378 405 413 534 573
Fixed Assets + 50 50 46 46 55 94 91 120 125 184 182
CWIP 0 0 0 5 0 6 26 0 0 0 4
Investments 7 9 6 23 36 43 64 66 93 109 174
Other Assets + 66 80 85 101 89 165 197 219 196 241 214
Total Assets 123 140 138 175 180 308 378 405 413 534 573
Equity Capital 22 78 78 78 78 86 94 94 94 94 94

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 6 7 0 24 14 16 11 -6 23 58
Cash from Investing Activity + 0 -4 1 -23 -18 -27 -45 83 -18 -51
Cash from Financing Activity + -6 -1 1 -2 5 8 35 -15 -68 -3
Net Cash Flow -1 2 2 -1 1 -2 1 62 -63 4
Free Cash Flow 3 4 -3 21 2 5 -10 -14 13 46
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 76 66 32 176 108 113 86 7 70 105

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 50.57% → 50.57%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 49.44% 49.35% 49.34% 49.34% 49.3% 49.32% 49.02% 49.33% 49.17% 49.23% 49.07% 47.2%
Promoters 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57%
FII 0.0% 0.08% 0.09% 0.1% 0.13% 0.11% 0.41% 0.1% 0.26% 0.21% 0.35% 2.23%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Syncom Formu (i) Ltd (this stock) 1,907 20.0 4.06 17.6%
Beta Drugs Limited 1,990 38.3 4.54 18.8%
Hester Biosciences Ltd 1,992 33.9 4.26 15.9%
Venus Remedies Limited 2,002 16.4 2.84 15.6%
Ngl Fine Chem Limited 1,783 27.9 4.92 17.4%
Suraksha Diagnostic Ltd 1,780 42.6 6.45 14.2%
Windlas Biotech Limited 2,067 31.1 3.64 12.2%

Which Mutual Funds Hold Syncom Formu (i) Ltd?

Frequently Asked Questions about Syncom Formu (i) Ltd

Community Sentiment

What are other investors saying about Syncom Formu (i) Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.